Getting tested for Alpha-1 is easy. It is diagnosed with simple blood tests. Find out about a free Grifols AlphaKit you can get from your doctor.

What Is AAT Deficiency?

Alpha1-antitrypsin (AAT) deficiency (also known as Alpha-1) develops when your body has a lower than normal level of the protein AAT. It is a genetic disorder, so it is inherited.2

Because Alpha patients have low levels of the protective protein called AAT in their blood, this allows certain enzymes to attack healthy tissues in the body, primarily in the lungs. Such destruction can lead to serious lung disease (such as emphysema), liver conditions, and skin conditions.

AAT plays a critical role in protecting your lungs1

Promo 1
Promo 2
Promo 3
Protecting Lungs Images Key
Scroll Left
Neutrophils mobilize, delivering elastase at the alveolar surface in
response to bacterial infections, environmental pollutants, or tobacco exposure.
Normal AAT levels keep neutrophil elastase in check.
AAT inhibits excess elastase; lung structure preserved.
Low levels of AAT leave lung tissue unprotected.
Excess elastase cannot be neutralized; lung elastin destroyed; lung function compromised.
Scroll Right

Click arrows to advance images.

next: Prevalence of Alpha-1 >

Important Safety Information

PROLASTIN®-C (alpha1-proteinase inhibitor [human]) is indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe deficiency of alpha1-proteinase inhibitor (alpha1-antitrypsin deficiency).

The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI), including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.

PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.

PROLASTIN-C is contraindicated in IgA-deficient patients with antibodies against IgA due to risk of hypersensitivity.

Hypersensitivity reactions may occur. Should evidence of hypersensitivity reaction be observed, promptly stop infusion and begin appropriate therapy.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. PROLASTIN-C is contraindicated in patients with antibodies against IgA.

The most common drug-related adverse reaction observed at a rate of > 5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.

Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying PROLASTIN-C full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 11-800-FDA-1088

References
  1. Köhnlein T, Welte T. Alpha-1 Antitrypsin Deficiency: Clinical Aspects and Management. Bremen, Germany: Uni-Med Verlag AG; 2007:16-39.
  2. What is Alpha-1? Alpha-1 Foundation. http://www.alphaone.org/healthcare/?c=01.what is alpha-1